GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
77
c/survodutide·posted 11 days ago by u/peak_area_pete

[Discussion] small community, high signal, let us keep it that way

Discussion

Trying to settle this properly because the thread from last year went in circles.

The claim: MASH matters. The counter-claim: it is measurement error. Both sides have been asserting it confidently for about 14 months without either producing anything.

What would actually settle it is 11 people measuring the same thing the same way. I have started; my numbers are below. They lean one way but not strongly enough for me to declare victory.

If you have data, post the data. If you have an opinion, flair it as an opinion.

121 up / 44 down73% upvoted9 commentsid 18w76y18 Jul 2026

9 comments

9 in this archive, depth 5

best — the order this archive was captured in

u/peak_area_peteanalytical10 points·9 days ago

the MASH indication changes the risk calculus

replysharereportpermalink
u/clara_restrepo7 points·10 days ago

Crossposting this to c/tirzepatide because the people who need it are not reading this community.

replysharereportpermalink
[deleted]3 points·10 days ago

[deleted]

replysharereportpermalink
u/renzo_asante2 points·9 days ago

[deleted]

Yes, exactly this, and it is the bit that took me 14 weeks to accept.

replysharereportpermalink
u/diego_szabo1 point·9 days ago·edited

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

replysharereportpermalink
u/sofia_ferreira1 point·9 days ago

phase 15 data is interesting, phase 30 will be different

replysharereportpermalink
u/peak_area_peteOPanalytical0 points·9 days ago

Came off after 62 weeks for financial reasons. Regained about a third over the following year. Back on now at a much lower dose.

replysharereportpermalink
u/fibre_forward4 points·10 days ago

phase 4 data is interesting, phase 32 will be different

replysharereportpermalink
u/peak_area_peteOPanalytical2 points·10 days ago

not approved, descriptive posts only

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →